CGRP monoclonal antibodies (mAbs)
- Migraine-prevention biologics
- Monthly/quarterly injection; rapid onset possible
- Erenumab blocks receptor; others bind ligand
- Minimal CYP drug interactions
- Constipation/hypertension notable with erenumab
- Injection-site reactions are common
- Now accepted as first-line preventive options
Class at a glance
- Migraine-prevention biologics
Pharmacology
- Erenumab blocks receptor; others bind ligand
- Minimal CYP drug interactions
Dosing / safety
- Monthly/quarterly injection; rapid onset possible
- Constipation/hypertension notable with erenumab
Safety / clinical role
- Injection-site reactions are common
- Now accepted as first-line preventive options
Drugs in this class (3)
All drug classes · Open the interactive console ↗
